Chronological coverage updated 10th September 2026 11:56.
Update 1 · 10th September 2026
NHS Misses 62-Day Treatment Target for Nearly Half of Aggressive Lymphoma Patients
A major healthcare audit has revealed that thousands of patients diagnosed with fast-growing blood cancer face severe delays before commencing medical therapy. Aggressive, high-grade non-Hodgkin lymphoma advances rapidly and routinely demands immediate medical intervention. However, health service providers across England and Wales are routinely failing to meet baseline referral-to-treatment timelines. Sources: hippocraticpost.com.
44% of patients in England diagnosed with aggressive non-Hodgkin lymphoma do not start treatment within the standard NHS target of 62 days from initial referral. — according to National Non-Hodgkin Lymphoma Audit, as reported by hippocraticpost.com.
38% of non-Hodgkin lymphoma patients in Wales miss the 62-day operational target from referral to treatment start. — according to National Non-Hodgkin Lymphoma Audit, as reported by hippocraticpost.com.
The findings from the National Non-Hodgkin Lymphoma Audit highlight significant systemic bottlenecks within cancer diagnostic and treatment pathways, prompting calls from healthcare professionals to safeguard emergency oncology access and reduce diagnostic referral backlogs. Sources: hippocraticpost.com.
- 44% of aggressive non-Hodgkin lymphoma patients in England experience care delays beyond the 62-day national threshold.
- In Wales, 38% of patients with high-grade blood cancer do not receive treatment within the required 62 days.
- Delayed treatment for fast-growing cancers places patients at elevated risk of severe disease progression.
Sources: hippocraticpost.com